Navigation Links
Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied

NOAA/Virginia Sea Grant has awarded Virginia Tech $119,000 to study whether high hydrostatic pressure will inactivate Hepatitis A virus in both shucked and unshucked oysters.

The project, led by Daniel Holliman, an M.D. with the High Pressure Processing Laboratory, and Laura Douglas, lab manager, will identify one or more effective high pressure processing schedules. The laboratory is a facility of the Department of Food Science and Technology at Virginia Tech, devoted to improving food safety and food processing.

Hepatitis A virus (HAV) is one of the more serious illnesses transmissible by shellfish. Worldwide, HAV is responsible for more than 1.5 million cases of the disease each year, with 260,000 cases and more than 100 deaths in the United States. Hepatitis A infection is characterized by fatigue, malaise, fever, loss of appetite, nausea, vomiting, joint and muscle aches, and abdominal pain, coupled with the onset of jaundice, a yellowing of the whites of the eyes, and dark urine. The disease generally runs its course in two months, but can linger as long as six. While survival rates for Hepatitis A are above 99 percent, the disease can be very dangerous for infants, the elderly, immunosuppressed people, and those with existing liver disease.

Bivalve shellfish, such as oysters, have been demonstrated to concentrate pathogenic organisms from their environment. In some cases, sewage contamination of harvesting areas, either from coastal runoff or ship discharges, has been shown to result in HAV contamination of oysters. Several studies have demonstrated remarkable concentration and persistence of HAV in shellfish exposed to the virus through their surrounding seawater. Even with depuration, HAV may persist in oysters for several weeks after exposure. The virus also is fairly resistant to heating and may remain viable in shellfish after up to five minutes of steaming.

For these reasons, high hydrostatic pressure treatment of raw oyst
'"/>

Source:Virginia Tech


Page: 1 2

Related biology news :

1. Gene therapy to lower blood pressure just enough
2. Researchers learn how blood vessel cells cope with their pressure-packed job
3. Genes affecting blood pressure change as children become adults
4. How nice, brown rice: Study shows rice bran lowers blood pressure in rats
5. Blame the brain for high blood pressure
6. Its OK for men with high blood pressure to have a drink or two, new study finds
7. 8 plants from South Africa may hold potential for treating high blood pressure
8. Scientists Replicate Hepatitis C Virus in Laboratory
9. Norovirus, AIDS vaccine and Hepatitis Virus
10. UCLA study assesses cost-effectiveness of Hepatitis B drugs
11. Natural Killers Could Lead to New Hepatitis Treatments

Post Your Comments:
(Date:11/24/2009)...of debate. A high-profile study a few years ago su...arbon from trees and leaves, evidence for a very c...ystems. , But new research from the University o...Algae provide a much richer diet for fish and othe...is week in the Proceedings of the National Academ...
(Date:11/23/2009)...vidence that the "synergistic" effect of early-lif...on and indoor endotoxin causes more harm to develo... , Environmental health scientists at the Univer...hown that children exposed to both high levels of ...ing early life are six times more likely to experi...
(Date:11/23/2009)...of day matters to forest trees dealing with drough... team led by Professor Malcolm Campbell, Universit...arch and colleagues in the department of cell and ...pitalizing on their previous work to decode the ge...d how poplar trees use their 45,000 genes to respo...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Atlantic Pharmaceuticals Inc Announces Completion of Successful Pre IND Meeting with FDA for Abuse Deterrent Narcotic 49728 1Atlantic Pharmaceuticals Inc Announces Completion of Successful Pre IND Meeting with FDA for Abuse Deterrent Narcotic 49728 2Austrian IT Solutions Provider x tention IT GmbH Implements Entrust Versatile Authentication Platform 49723 1Austrian IT Solutions Provider x tention IT GmbH Implements Entrust Versatile Authentication Platform 49723 2Austrian IT Solutions Provider x tention IT GmbH Implements Entrust Versatile Authentication Platform 49723 3ThromCat 28R 29 XT 28TM 29 Thrombectomy Catheter System Receives CE Mark 49718 1ThromCat 28R 29 XT 28TM 29 Thrombectomy Catheter System Receives CE Mark 49718 2ThromCat 28R 29 XT 28TM 29 Thrombectomy Catheter System Receives CE Mark 49718 3
...ist has discovered key appetite control cells in t...ased hunger and potentially weight-gain as we grow...oendocrinologist with Monash University,s Departme..., Dr Andrews found that appetite-suppressing cell...aid the degeneration is more significant following...
... many men during their fight against prostate canc...searchers have found. The findings were published ...edings of the National Academy of Sciences . , Th...edeviled patients for decades. Hormone therapy, a ...ncer, generally keeps the cancer at bay for a year...
...s(TM) Wireless Data Communications Link School ..., WALL, N.J., Aug. 20 BIO-key International,Inc....sed biometric,identification and wireless public s...of MobileSRO(TM) and MobileCampus(TM), silent, sec...-12 schools and higher,education, respectively., ...
Other Biology News:Killer carbs -- Monash scientist finds the key to overeating as we age 2Why a common treatment for prostate cancer ultimately fails 2Why a common treatment for prostate cancer ultimately fails 3Why a common treatment for prostate cancer ultimately fails 4BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses 2BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses 3
(Date:11/24/2009)..., SEATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCo...evelopmentAuthority(OPDA)wererecentlyawarded$2mill...ionBoard(CERB)inaprivate/publicpartnershiptoconstr...nLincolnCounty,WA. ,, "Thisinvestmentwillsignif...over70greenjobstoLincolnCounty,"saidBlueMarbleEner...
(Date:11/24/2009)..., DUBLIN,November24/PRNewswire-FirstCall/--Shire...pharmaceuticalcompany,today,announcedthatithassubm...rasealfa,thecompany,senzymereplacementtherapyindev...isthethirdmarketing,applicationforvelaglucerasealf...eUnitedStatesandCanada. , Basedonaglobalsuppl...
(Date:11/24/2009)... Program Connects Customers w...les Collected with DNA Genotek Products , ...009 -- DNA Genotek , a leading provider of produc... and preparation, today announced its new global p...ancements for DNA Genotek,s partner community and ...
(Date:11/23/2009)...AMPAIGN, Ill. You can think of it as origami ver...ity of Illinois have developed a technique for fab...icon structures from thin films by coupling photol...pillary interactions. , The films, only a few mic...ot possible with thicker pieces of the same materi...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2
.... 28 Beckman,Coulter, Inc. (NYSE: BEC ), announc...ents with Adventist Health to provide a broad rang...t approximately $36 million over,six years. Advent... care,system with facilities in California, Hawaii...scom.com/cgi-bin/prnh/20031202/BECLOGO ), Under t...
...um Drives 71% Year-Over-Year Growth in Core ... Calif., Oct. 28 Cepheid (Nasdaq:,CPHD) today rep....9,million, an increase of 24% over the third quar...$(0.11) per share, which compares to revenue of $3....09) per share, in the third,quarter of fiscal 200...
...ovavax, Inc.,(Nasdaq: NVAX ) a clinical-stage vac...vi, President and Chief Executive Officer, will be... am. (PT) on October 30, 2008 at the,Palace Hotel ...vide an,overview of the company,s strategy, resear...esentation can be accessed via the Company website...
Other Biology Technology:Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care 2Cepheid Reports Third Quarter Revenue of $44.9 Million 2Cepheid Reports Third Quarter Revenue of $44.9 Million 3Cepheid Reports Third Quarter Revenue of $44.9 Million 4Cepheid Reports Third Quarter Revenue of $44.9 Million 5Cepheid Reports Third Quarter Revenue of $44.9 Million 6Cepheid Reports Third Quarter Revenue of $44.9 Million 7Cepheid Reports Third Quarter Revenue of $44.9 Million 8Cepheid Reports Third Quarter Revenue of $44.9 Million 9Cepheid Reports Third Quarter Revenue of $44.9 Million 10Cepheid Reports Third Quarter Revenue of $44.9 Million 11Cepheid Reports Third Quarter Revenue of $44.9 Million 12Cepheid Reports Third Quarter Revenue of $44.9 Million 13
Mouse Anti-Human CD182 (CXCR2) Monoclonal Antibody, Unconjugated, Clone 5E8/CXCR2 from BioLegend
Rabbit Anti-Human Purinergic Receptor P2Y12 Polyclonal Antibody, Unconjugated from IMGENEX
Goat Anti-Human AGAP1 / Centaurin, gamma 2 Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-Human CLAN Polyclonal Antibody, Unconjugated from IMGENEX
Biology Products: